MRI-guided focused ultrasound thalamotomy is more effective than deep brain stimulation and significantly cheaper.
News
Electroconvulsive therapy might be safe and reliable therapy for treatment of psychiatric symptoms in patients with Huntington disease.
Long-term valbenazine may be beneficial in managing tardive dyskinesia in schizophrenia.
Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.
De novo likely gene disrupting variants were highly overrepresented in the Tourette’s cases compared with unaffected parent and sibling sample controls.
The results add to the growing body of evidence in support of deep brain stimulation for refractory Tourette syndrome.
A 150-year-old drug, apomorphine, may reduce off time in patients with Parkinson’s disease.
Previous animal model studies have shown PEA to be beneficial in neuroinflammation and provide neuroprotection.
Transcranial Doppler during head-up tilting may be useful for evaluating dizziness.
People with HBV were 76% more likely and those with HCV were 51% more likely to develop PD than people in the comparison group.
Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.
A significant association was found between the apnea-hypopnea index and Epworth Sleepiness Scale scores.
Researchers have developed an assay that accurately identifies small quantities of α-synuclein in cerebrospinal fluid.
Deutetrabenazine is only the second drug approved for patients with Huntington’s disease.
There were slower declines in health-related quality of life and mobility when exercise was increased by 30 minutes/week.
The US FDA has approved safinamide as adjunctive therapy in Parkinson’s disease to increase “on” time
While their are other factors more strongly associated with risk of cerebral palsy, maternal obesity is modifiable and therefore should be studied further.
Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.
Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson’s disease.
During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson’s disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve “off” periods.
The small study documented several cases of denervation and increased thermal thresholds in patients treated with LCIG.
The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers.
The pathogenesis of GBA on PD is unclear, although several studies have pointed to disruptions of different molecular pathways that contribute to disease onset.
Several strategies for clinical practice and research may reduce the cost of MS treatment while maintaining efficacy.
Smoking during pregnancy has been linked withlong-term neurodevelopmental abnormalities and child behavioral problems.
Patients in the treatment group experienced significant improvements at 3 months and through 12 months.
